Skip to main content
logo
Metagenomi Therapeutics, Inc. (MGX)
NASDAQ: MGX · Real-Time Price · USD
1.165
-0.005 (-0.43%)
Sep 8, 2026, 12:38 PM EDT - Market open

Metagenomi Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Market Capitalization
4461135---
Market Cap Growth
-34.49%-54.98%----
Enterprise Value
-39-82-93---
Last Close Price
1.171.623.61---

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
3.262.412.58---
PB Ratio
0.390.380.57---
P/TBV Ratio
0.390.380.57---

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
0.340.260.200.220.071.11
Debt / FCF Ratio
----1.182.29
Net Debt / Equity Ratio
-0.74-0.76-0.86-1.04-1.26-1.35
Net Debt / EBITDA Ratio
0.871.332.433.008.012.51
Net Debt / FCF Ratio
0.971.341.812.20-21.82-2.77
Asset Turnover
0.060.090.150.120.06-
Quick Ratio
4.407.086.733.997.494.32
Current Ratio
4.507.226.914.047.564.33
Return on Equity (ROE)
-60.61%-44.66%-34.69%-28.04%-27.62%-
Return on Assets (ROA)
-28.19%-21.99%-16.12%-12.59%-10.03%-
Return on Capital Employed (ROCE)
-68.80%-48.40%-30.90%-26.50%-12.20%-20.50%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-211.46%-144.46%-57.78%---
FCF Yield
-194.11%-147.09%-83.04%---
Buyback Yield / Dilution
-1.06%-12.79%-870.10%-0.15%40.27%-
SEC Filings: 10-K · 10-Q